Clinical Trial Update: 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3, 1-year study evaluated the efficacy, safety, and tolerability of glycopyrronium bromide (NVA237) in chronic obstructive pulmonary disease. The result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Glycopyrronium bromide (NVA237) (glycopyrronium bromide)

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-07-27